T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ExxonMobil
XOM
|
+$1.76B |
| 2 |
Eli Lilly
LLY
|
+$1.4B |
| 3 |
Bank of America
BAC
|
+$1.3B |
| 4 |
Tesla
TSLA
|
+$1.19B |
| 5 |
Wells Fargo
WFC
|
+$784M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$6.47B |
| 2 |
Amazon
AMZN
|
+$3.71B |
| 3 |
Yum! Brands
YUM
|
+$2.84B |
| 4 |
Salesforce
CRM
|
+$2.77B |
| 5 |
Fortive
FTV
|
+$2.41B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.06% |
| 2 | Healthcare | 18.72% |
| 3 | Consumer Discretionary | 14.62% |
| 4 | Financials | 10.36% |
| 5 | Communication Services | 9.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1001
Warner Music
WMG
$13.3B
| $13.9M | ﹤0.01% |
599,708
-706,084
| -54% | -$19.4M |
|
1002
Boston Properties
BXP
$11B
| $13.7M | ﹤0.01% |
183,246
+207
| +0.1% | +$17.6K |
|
|
IPG
1003
DELISTED
Interpublic Group of Companies
IPG
| $13.7M | ﹤0.01% |
534,933
-9,416
| -2% | -$267K |
|
|
NVRO
1004
DELISTED
NEVRO CORP.
NVRO
| $13.5M | ﹤0.01% |
290,533
-728,899
| -72% | -$33.8M |
|
1005
Henry Schein
HSIC
$10B
| $13.5M | ﹤0.01% |
205,603
-9,053
| -4% | -$672K |
|
1006
Seagate
STX
$209B
| $13.5M | ﹤0.01% |
253,196
+7,808
| +3% | +$564K |
|
1007
Adaptive Biotechnologies
ADPT
$3.89B
| $13.5M | ﹤0.01% |
1,892,084
-10,291,811
| -84% | -$96.9M |
|
1008
Novartis
NVS
$288B
| $13.3M | ﹤0.01% |
94,603
+53,220
| +129% | +$4.41M |
|
|
DCPH
1009
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $13.3M | ﹤0.01% |
716,757
+569,958
| +388% | +$8.94M |
|
1010
Weatherford International
WFRD
$6.6B
| $13.2M | ﹤0.01% |
409,333
+384,789
| +1,568% | +$9.61M |
|
1011
NRG Energy
NRG
$25.2B
| $13.2M | ﹤0.01% |
345,090
-9,549
| -3% | -$381K |
|
1012
Ginkgo Bioworks
DNA
$488M
| $13.2M | ﹤0.01% |
105,398
+657
| +0.6% | +$78.3K |
|
1013
Pultegroup
PHM
$24.9B
| $13.1M | ﹤0.01% |
348,000
-8,255
| -2% | -$347K |
|
1014
National Vision
EYE
$1.51B
| $12.9M | ﹤0.01% |
393,947
-122,066
| -24% | -$3.97M |
|
1015
CI&T Inc
CINT
$474M
| $12.8M | ﹤0.01% |
1,362,842
+9,881
| +0.7% | +$105K |
|
|
VMW
1016
DELISTED
VMware, Inc
VMW
| $12.8M | ﹤0.01% |
119,955
+7,164
| +6% | +$825K |
|
1017
Certara
CERT
$1.24B
| $12.7M | ﹤0.01% |
957,585
-1,867,940
| -66% | -$34.5M |
|
1018
JetBlue
JBLU
$2.19B
| $12.7M | ﹤0.01% |
1,911,243
+400,772
| +27% | +$3.26M |
|
|
BWIN
1019
Baldwin Insurance Group
BWIN
$2.99B
| $12.6M | ﹤0.01% |
478,779
-4,836,549
| -91% | -$138M |
|
1020
Enanta Pharmaceuticals
ENTA
$391M
| $12.5M | ﹤0.01% |
240,687
+52,344
| +28% | +$3.06M |
|
1021
VF Corp
VFC
$5.79B
| $12.4M | ﹤0.01% |
414,508
+1,105
| +0.3% | +$47.7K |
|
1022
Dime Commercial Bancshares
DCOM
$1.82B
| $12.3M | ﹤0.01% |
420,640
-2,794,146
| -87% | -$88.9M |
|
1023
WEX
WEX
$6.78B
| $12.3M | ﹤0.01% |
97,026
+647
| +0.7% | +$102K |
|
1024
Robert Half
RHI
$4.48B
| $12.2M | ﹤0.01% |
160,104
-2,356
| -1% | -$184K |
|
1025
Advance Auto Parts
AAP
$3.46B
| $12.2M | ﹤0.01% |
78,318
-746
| -0.9% | -$136K |
|
Similar funds
T. Rowe Price Associates's Q3 2022 Portfolio in Review
As of Q3 2022, T. Rowe Price Associates held 3,114 positions worth $610B, down 23% from $791B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
T. Rowe Price Associates withdrew a net $168B in Q3 2022, closing 171 positions and reducing 1,248 holdings. Its most notable exit was Alcon, an estimated $1.51B position sold in full.
By sector, the portfolio is most concentrated in Technology at 26% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, T. Rowe Price Associates opened a new position in Corebridge Financial worth $194M.
- T. Rowe Price Associates's largest Q3 2022 buy was Corebridge Financial: 9,831,688 shares worth $194M.
- T. Rowe Price Associates added most to ExxonMobil in Q3 2022, an estimated $1.76B increase.
- T. Rowe Price Associates's biggest Q3 2022 reduction was Microsoft, cutting an estimated $6.47B.
- T. Rowe Price Associates fully exited Alcon in Q3 2022, selling an estimated $1.51B.
- T. Rowe Price Associates's ten largest holdings make up 31% of its $610B portfolio in Q3 2022.
- T. Rowe Price Associates opened 154 new positions and closed 171 in Q3 2022.
- T. Rowe Price Associates's portfolio value fell 23% quarter-over-quarter to $610B.
Based on T. Rowe Price Associates's 13F filing for Q3 2022, filed 14 Nov 2022.